Clinical Trials Sponsored by Biogen Idec

Total 2129 results

Biogen
Biogen Idec A/S

Completed

A Single-blinded, Controlled, Multi-centre Study of Effects of Exercise in Participants With Multiple Sclerosis (ACTIMS)

Exercise

Sweden, Finland, New Zealand, Denmark, Norway, Australia
Stanford University
Genentech and Biogen IDEC

Completed

Rituximab for Pediatric Renal Transplant Rejection

Kidney Transplantation

United States
IDEA AG

Completed

Safety and Efficacy of Two Dosages of Diractin® in Osteoarthritis (OA)

Osteoarthritis of the Knee

Poland, United Kingdom, Czech Republic, Germany
IDEA AG

Completed

Multi-Centre, Open-Label, Two Segment, Study Comparing Plasma Pharmacokinetics of Ketoprofen in Diractin® Alone to Diractin® Applied Concomitant With Heat or Moderate Exercise

Pharmacokinetic

Germany
IDEA AG

Completed

IDEA-033 Open Label Study

Joint Pain | Musculoskeletal Pain | Stiffness | Soft Tissue Inflammation in Designated Target Area(s)

Germany
IDEA AG

Completed

Study of Safety and Efficacy of Diractin® for the Treatment of Osteoarthritis (OA) of the Knee

Osteoarthritis of the Knee

United States
IDEA AG

Completed

Effect of IDEA-070 on Pain and Inflammation Induced by PDT

Actinic Keratosis

Germany
IDEA AG

Completed

IDEA-033 Three Months Dose Finding in OA Followed by IDEA-033 Three Months Extension in OA

Osteoarthritis; Knee
IDEA AG

Completed

Ketoprofen in Transfersome Compared to Oral Celecoxib and Placebo for Pain Associated With Osteoarthritis of the Knee

Osteoarthritis, Knee
IDEA AG

Completed

Multiple Dose, Double-Blind, Placebo and Active Controlled Study of Pharmacokinetics of Diractin® as Well as Safety and Efficacy for the Treatment of Muscle Soreness

Muscle Soreness

Germany
IDEA AG

Completed

An Effectiveness and Safety Study of IDEA-033 in Comparison to Oral Naproxen and Placebo for the Treatment of Osteoarthritis of the Knee

Osteoarthritis, Knee

United States
IDEA AG

Completed

A Long-Term Safety Study of IDEA-033 in Comparison to Oral Naproxen for the Treatment of Osteoarthritis of the Knee

Osteoarthritis, Knee

United States
Biogen

Recruiting

A Study to Look at How a Single Oral Dose of Carbon-14-Labelled [14C] BIIB091 Moves Through and is Processed by the Body in Healthy Male Participants (Mass Balance)

Healthy Volunteer

United States
Biogen

Not yet recruiting

A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS)

Multiple Sclerosis
Biogen

Recruiting

Virtual Reality for the Mitigation of Anxiety During Intrathecal Administration in Participants With Spinal Muscular Atrophy (REALITY)

Spinal Muscular Atrophy (SMA)

France
Biogen

Recruiting

A Study for Tysabri Participant Preference

Relapsing-Remitting Multiple Sclerosis (RRMS)

Germany
Biogen

Recruiting

A Study to Evaluate Higher Dose (HD) Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy Previously Treated With Risdiplam (ASCEND)

Spinal Muscular Atrophy

United States, Germany, Italy, Hungary, Japan
Biogen

Recruiting

A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus (TOPAZ-2)

Lupus Erythematosus, Systemic

China, United States, Belgium, Netherlands, Japan, Romania, Serbia, Canada, Germany, Hungary, Italy, Puerto Rico, Israel, Argentina, Colombia, Czechia, United Kingdom
Biogen

Recruiting

A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

Spain, Germany, Croatia, Turkey, Saudi Arabia, Hungary, Belgium, Australia, France, Portugal, Slovakia, United States, Bulgaria, Greece, Kuwait, Russian Federation, Tunisia, Italy, Argentina, Czechia, Israel, Serbia
Biogen

Enrolling by invitation

A Long-Term Extension Study to Evaluate Continuous Safety and Efficacy of BIIB059 (Litifilimab) in Adults With Active Subacute Cutaneous Lupus Erythematosus (CLE) and/or Chronic CLE With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy (AMETHYST LTE)

Subacute Cutaneous Lupus Erythematosus | Chronic Cutaneous Lupus Erythematosus

France, Spain, United States, Sweden
Biogen

Active, not recruiting

Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy (DEVOTE)

Muscular Atrophy, Spinal

China, United States, Netherlands, Spain, Korea, Republic of, Taiwan, Australia, Canada, Chile, Saudi Arabia, Poland, Israel, Brazil, Russian Federation, Hungary, Japan, United Kingdom, Italy, Germany, Estonia, Greece, Mexico, Colombia and more
Biogen

Completed

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BIIB107 in Healthy Adult Participants

Healthy Volunteers

United States
Biogen

Completed

Tysabri Observational Cohort Study - Multiple Sclerosis (MS) Registries

Progressive Multifocal Leukoencephalopathy

United States
Biogen

Enrolling by invitation

Extension Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy Who Previously Participated in a Study With Nusinersen (ONWARD)

Muscular Atrophy, Spinal

United States, Spain, Taiwan, Chile, Saudi Arabia, Brazil, Russian Federation, Mexico, Germany, Estonia, Japan, Canada, Colombia, Lebanon, Poland, Italy, China
Biogen

Completed

Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants (TYPIFI)

Relapsing Remitting Multiple Sclerosis

Portugal
Biogen

Completed

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics, With Target Occupancy Study of BIIB113 in Healthy Participants

Healthy Volunteer

United Kingdom, Sweden
Biogen

Completed

A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using BIIB112 (XIRIUS)

X-Linked Retinitis Pigmentosa

United States, United Kingdom
Biogen

Terminated

A Study to Evaluate the Safety, Tolerability, and Efficacy of SAGE-217 Compared to Placebo in Adult Participants With Comorbid Major Depressive Disorder (MDD) and Insomnia

Insomnia | Major Depressive Disorder

United States
Biogen

Completed

A Study to Assess the Pharmacodynamic Effects of SAGE-217 in Healthy Adults Using an Insomnia Model

Healthy

United States
Biogen

Terminated

A Study to Evaluate SAGE-217 for Prevention of Relapse in Adult Participants With Major Depressive Disorder

Major Depressive Disorder

United States
Biogen

Completed

Study to Evaluate BIIB059 (Litifilimab) in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE) (LILAC)

Systemic Lupus Erythematosus | Active Cutaneous Lupus Erythematosus

United States, Taiwan, Philippines, Argentina, Poland, Israel, Bulgaria, Serbia, Mexico, Colombia, Korea, Republic of, Thailand
Biogen

Active, not recruiting

A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic Mutation (ALSpire)

Amyotrophic Lateral Sclerosis

United States, Netherlands, Italy, Canada
Biogen

Completed

Plegridy Satisfaction Study in Participants (PLATINUM)

Relapsing-Remitting Multiple Sclerosis (RRMS)

Italy
Biogen

Completed

Efficacy and Safety of BG00012 in MS

Multiple Sclerosis

Russian Federation, Sweden, Germany, Poland, Hungary, United Kingdom, Netherlands, Switzerland, Turkey, Czechia
Biogen

Completed

Alternate Dosing Regimens of BG00012 in Healthy Volunteers (109HV106)

Healthy

United States
Biogen

Terminated

A Pharmacokinetics and Safety Study of BIIB132 in Adults With Spinocerebellar Ataxia 3

Spinocerebellar Ataxia Type 3

United States, Netherlands, Israel, Portugal, United Kingdom, Germany
Biogen

Approved for marketing

Expanded Access Program for Tofersen in Participants With Superoxide Dismutase 1-Amyotropic Lateral Sclerosis

Superoxide Dismutase 1-Amyotropic Lateral Sclerosis

United States
Biogen

Completed

Dimethyl Fumarate (DMF) Observational Study (ESTEEM)

Multiple Sclerosis

United States, Denmark, Italy, Netherlands, Switzerland, Canada, Australia, New Zealand, United Kingdom, Slovakia, Austria, Hungary, Czechia, Portugal, Germany, Spain, Poland, Puerto Rico, France, Argentina, Ireland, Norway
Biogen

Terminated

Exploring Diroximel Fumarate Real-world Experience in Canada and Israel (EXPER-CA/IL)

Relapsing Forms of MS

Israel
Biogen

Completed

Study to Investigate Pregnancy Outcomes in Female Participants Exposed to Subcutaneous (SC) Peginterferon Beta-1a and Intramuscular (IM) Interferon Beta-1a Reported in a German Participant Support Program

Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting

Germany
Biogen

Completed

A Study to See How BIIB122 Works in the Human Body, and to Evaluate it's Safety, and Tolerability in Healthy Adult Japanese, Chinese, and Caucasian Participants

Healthy Volunteer

United States
Biogen

Terminated

Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease (TANGO)

Alzheimer's Disease

United States, Spain, Italy, Australia, France, Poland, Germany, Japan, Sweden
Biogen

Completed

Biogen Multiple Sclerosis Pregnancy Exposure Registry

Multiple Sclerosis | Exposure During Pregnancy

Spain, Italy, Australia, Poland, United Kingdom, United States, Canada, France, Germany, Ireland
Biogen

Completed

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis

United States, Canada, United Kingdom, Ireland, Netherlands, Switzerland
Biogen

Completed

Multiple Ascending Doses of PF-04958242 in Subjects With Stable Schizophrenia (MAD)

Schizophrenia

United States
Biogen

Terminated

221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease (ENGAGE)

Alzheimer's Disease

United States, Spain, Italy, Taiwan, Australia, Denmark, Portugal, Korea, Republic of, Canada, Japan, France, United Kingdom, Austria, Germany
Biogen

Completed

A Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of BIIB091, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Healthy Adult Participants

Healthy Volunteer

United States
Biogen

Completed

A Study to Explore Pharmacodynamic Effects of BIIB104 on Brain Circuitry in Healthy Participants

Healthy Volunteers

United Kingdom
Biogen

Completed

A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA) (CHERISH)

Spinal Muscular Atrophy

United States, Germany, Spain, Canada, France, Hong Kong, Italy, Japan, Korea, Republic of, Sweden
Biogen

Completed

Safety, Tolerability and Pharmacokinetics of BIIB118 (PF-05251749)

Healthy

United States

3

Subscribe